JP2015120685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015120685A5 JP2015120685A5 JP2014236875A JP2014236875A JP2015120685A5 JP 2015120685 A5 JP2015120685 A5 JP 2015120685A5 JP 2014236875 A JP2014236875 A JP 2014236875A JP 2014236875 A JP2014236875 A JP 2014236875A JP 2015120685 A5 JP2015120685 A5 JP 2015120685A5
- Authority
- JP
- Japan
- Prior art keywords
- embolism
- thrombosis
- venous
- thromboembolic
- arterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 18
- 208000005189 Embolism Diseases 0.000 claims 12
- 206010062599 Arterial occlusive disease Diseases 0.000 claims 4
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 230000000271 cardiovascular Effects 0.000 claims 4
- 230000000302 ischemic Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- DCBBOIFLGAMQFC-SFTDATJTSA-N 4-[[(2S,4S)-1-(4-carbamimidoylbenzoyl)-4-(4-methylsulfonylpiperazin-1-yl)pyrrolidine-2-carbonyl]amino]benzoic acid Chemical compound C1CN(S(=O)(=O)C)CCN1[C@@H]1CN(C(=O)C=2C=CC(=CC=2)C(N)=N)[C@H](C(=O)NC=2C=CC(=CC=2)C(O)=O)C1 DCBBOIFLGAMQFC-SFTDATJTSA-N 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003658 Atrial fibrillation Diseases 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 2
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 2
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 2
- 208000002528 Coronary Thrombosis Diseases 0.000 claims 2
- 210000004351 Coronary Vessels Anatomy 0.000 claims 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 210000004185 Liver Anatomy 0.000 claims 2
- 210000003975 Mesenteric Arteries Anatomy 0.000 claims 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000006193 Pulmonary Infarction Diseases 0.000 claims 2
- 206010063544 Renal embolism Diseases 0.000 claims 2
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000001269 cardiogenic Effects 0.000 claims 2
- 230000002490 cerebral Effects 0.000 claims 2
- 201000008739 coronary artery disease Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 201000010849 intracranial embolism Diseases 0.000 claims 2
- 201000001429 intracranial thrombosis Diseases 0.000 claims 2
- 230000002093 peripheral Effects 0.000 claims 2
- 230000003836 peripheral circulation Effects 0.000 claims 2
- 201000009454 portal vein thrombosis Diseases 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrugs Drugs 0.000 claims 2
- 230000001737 promoting Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000007196 sexual disease Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 201000005060 thrombophlebitis Diseases 0.000 claims 2
- 230000001052 transient Effects 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 108010080805 Factor XIa Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014236875A JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013241680 | 2013-11-22 | ||
| JP2013241680 | 2013-11-22 | ||
| JP2014236875A JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015120685A JP2015120685A (ja) | 2015-07-02 |
| JP2015120685A5 true JP2015120685A5 (fr) | 2017-06-29 |
| JP6337750B2 JP6337750B2 (ja) | 2018-06-06 |
Family
ID=53532687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014236875A Expired - Fee Related JP6337750B2 (ja) | 2013-11-22 | 2014-11-21 | 化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6337750B2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160668A1 (fr) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia |
| EP3988549A1 (fr) | 2014-01-31 | 2022-04-27 | Bristol-Myers Squibb Company | Macrocycles avec des groupes p2' hétérocycliques en tant qu'inhibiteurs du facteur xia |
| NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
| WO2016036893A1 (fr) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamides macrocycliques qui sont des inhibiteurs de fxia |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| KR102595723B1 (ko) | 2016-06-21 | 2023-10-27 | 오리온 옵탈몰로지 엘엘씨 | 헤테로시클릭 프롤린아미드 유도체 |
| WO2019028362A1 (fr) * | 2017-08-04 | 2019-02-07 | Dyax Corp. | Inhibiteurs de la kallikréine plasmatique et utilisations associées |
| EP3854783A4 (fr) | 2018-09-20 | 2021-09-08 | ONO Pharmaceutical Co., Ltd. | Nouveau sel d'acide 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(méthylsulfonyl)pipérazin-1-yl]-l-prolyl\}amino)benzoïque et nouvelle forme cristalline dudit sel |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517060A (ja) * | 2000-11-07 | 2004-06-10 | ブリストルーマイヤーズ スクイブ カンパニー | セリンプロテアーゼ抑制剤として有用な酸誘導体 |
| ATE337000T1 (de) * | 2003-06-18 | 2006-09-15 | Merck Patent Gmbh | Pyrrolidin-1,2-dicarbonsäure-1- (4-ethinyl- phenyl)-amidö-2- (phenyl)-amidö derivate als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen |
| WO2007131982A2 (fr) * | 2006-05-16 | 2007-11-22 | Boehringer Ingelheim International Gmbh | Prolinamides substitués, procédé de production et utilisation de ceux-ci comme médicaments |
| TW201011006A (en) * | 2008-06-16 | 2010-03-16 | Nuevolution As | IAP binding compounds |
| GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2014
- 2014-11-21 JP JP2014236875A patent/JP6337750B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015120685A5 (fr) | ||
| JP2015524443A5 (fr) | ||
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| RU2014152276A (ru) | Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний | |
| JP2010526103A5 (fr) | ||
| JP2014530240A5 (fr) | ||
| JP2016027060A5 (fr) | ||
| RU2017124150A (ru) | Производное дигидроиндолизинона | |
| JP2018514535A5 (fr) | ||
| JP2019519533A5 (fr) | ||
| JP2013510144A5 (fr) | ||
| JP2016539098A5 (fr) | ||
| JP2017519020A5 (fr) | ||
| JOP20220058A1 (ar) | بروتينات اندماج علاجية | |
| JP2017505809A5 (fr) | ||
| Pella et al. | Pleiotropic effects of statins | |
| JP2016512243A5 (fr) | ||
| Yap et al. | A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation | |
| MY195760A (en) | Use of IDHP in Preparation of Drug or Health Product for Prevention and Treatment of Coronary Atherosclerosis Disease | |
| JPWO2020111268A5 (fr) | ||
| JP2010513430A5 (fr) | ||
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| JP2016523943A5 (fr) | ||
| JP2016088877A5 (fr) | ||
| Carrel et al. | Steroids and cardiopulmonary bypass: a never-ending story |